PA
OKUR

Perceptive Advisors’s OnKure Therapeutics OKUR Stock Holding History

Perceptive Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,004,439
Closed -$4.32M – 105
2025
Q1 		$4.32M Hold
1,004,439
– – 0.15% 68
2024
Q4 		$8.64M Buy
+1,004,439
New +$15.2M 0.24% 66

Other funds holding OKUR

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors's OKUR Position: Q2 2025 in Review

Perceptive Advisors sold out of OnKure Therapeutics (OKUR) in Q2 2025, closing a stake of 1,004,439 shares — an estimated $4.32M sold.

Perceptive Advisors first reported a position in OKUR in Q4 2024 and held it in 2 quarters. The position peaked at $8.64M in Q4 2024. 49 funds tracked by Wall St. Rank hold OKUR as of Q2 2025.

  • Perceptive Advisors reported no remaining OnKure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Perceptive Advisors sold 1,004,439 OnKure Therapeutics shares in Q2 2025, an estimated $4.32M.
  • Perceptive Advisors first reported a position in OnKure Therapeutics in Q4 2024 and held it in 2 quarters.
  • Perceptive Advisors's OnKure Therapeutics position peaked at $8.64M in Q4 2024.
  • 49 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.